Thrombolysis in patients with mild stroke results from the Austrian stroke unit registry

Stroke

Volumn 45, Issue 3, 2014, Pages 765-769

  Greisenegger, Stefan ^a   Seyfang, Leonhard ^b   Kiechl, Stefan ^c   Lang, Wilfried ^d   Ferrari, Julia ^d  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b DANUBE UNIVERSITY KREMS   (Austria)

^c INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^d KRANKENHAUS DER BARMHERZIGEN BRÜDER   (Austria)

Author keywords

Infarction; Stroke; Thrombolytic therapy

Indexed keywords

ALTEPLASE; FIBRINOLYTIC AGENT; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; AGED; ARTICLE; BLOOD CLOT LYSIS; BRAIN ISCHEMIA; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE SEVERITY; FEMALE; FIBRINOLYTIC THERAPY; FOLLOW UP; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANKIN SCALE; SENSITIVITY ANALYSIS; STROKE UNIT; AUSTRIA; CEREBROVASCULAR ACCIDENT; CONFIDENCE INTERVAL; INFARCTION; METHODOLOGY; MIDDLE AGED; REGISTER; RISK; STATISTICAL ANALYSIS; TREATMENT OUTCOME;

INFARCTION; STROKE; THROMBOLYTIC THERAPY;

AGED; AUSTRIA; CONFIDENCE INTERVALS; DATA INTERPRETATION, STATISTICAL; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; MALE; MIDDLE AGED; ODDS RATIO; REGISTRIES; STROKE; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 84899143608     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.113.003827     Document Type: Article

References (31)

1. Stecksen A, Asplund K, Appelros P, Glader EL, Norrving B, Eriksson M; Riks-Stroke Collaboration. Thrombolytic therapy rates and stroke severity: An analysis of data from the Swedish stroke register (Riks-Stroke) 2007-2010. Stroke. 2012;43:536-538.
2. Messe SR., Fonarow GC, Smith EE, Kaltenbach L, Olson DM, Kasner SE, et al. Use of tissue- Type plasminogen activator before and after publication of the European Cooperative Acute Stroke Study III in Get With The Guidelines-Stroke. Circ Cardiovasc Qual Outcomes. 2012;5: 321-326.
3. Fugate JE, Rabinstein AA. Contraindications to intravenous rtPA for acute stroke: A critical reappraisal. Neurol Clin Pract. 2013;3:177-185.
4. Barber PA, Zhang J, Demchuk AM, Hill MD, Buchan AM. Why are stroke patients excluded from TPA therapy? An analysis of patient eligibility. Neurology. 2001;56:1015-1020.
5. Cocho D, Belvfs R, Martf-Fibregas J, Molina-Porcel L, Dfaz-Manera J, Aleu A, et al. Reasons for exclusion from thrombolytic therapy following acute ischemic stroke. Neurology. 2005;64:719-720.
6. Smith EE, Fonarow GC, Reeves MJ, Cox M, Olson DM, Hernandez AF, et al. Outcomes in mild or rapidly improving stroke not treated with intravenous recombinant tissue- Type plasminogen activator: findings from Get With The Guidelines-Stroke. Stroke. 2011;42:3110-3115.
7. Khatri P, Conaway MR, Johnston KC; Acute Stroke Accurate Prediction Study (ASAP) Investigators. Ninety-day outcome rates of a prospective cohort of consecutive patients with mild ischemic stroke. Stroke. 2012;43:560-562.
8. Nedeltchev K, Schwegler B, Haefeli T, Brekenfeld C, Gralla J, Fischer U, et al. Outcome of stroke with mild or rapidly improving symptoms. Stroke. 2007;38:2531-2535.
9. The IST-3 Collaborative Group. The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): A randomised controlled trial. Lancet. 2012;379:2352-2363.
10. National Institute of Neurological Disorders Stroke rt-PA Stroke Study Group. Recombinant tissue plasminogen activator for minor strokes: The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study experience. Ann Emerg Med. 2005;46:243-252.
11. Fischer U, Baumgartner A, Arnold M, Nedeltchev K, Gralla J, De Marchis GM, et al. What is a minor stroke? Stroke. 2010;41:661-666.
12. Mishra NK, Lyden P, Grotta JC, Lees KR; VISTA Collaborators. Thrombolysis is associated with consistent functional improvement across baseline stroke severity: A comparison of outcomes in patients from the Virtual International Stroke Trials Archive (VISTA). Stroke. 2010;41:2612-2617.
13. Frank B, Grotta JC, Alexandrov AV, Bluhmki E, Lyden P, Meretoja A, et al; VISTA Collaborators. Thrombolysis in stroke despite contraindications or warnings? Stroke. 2013;44:727-733.
14. Ferrari J, Knoflach M, Kiechl S, Willeit J, Schnabl S, Seyfang L, et al; Austrian Stroke Unit Registry Collaborators. Early clinical worsening in patients with TIA or minor stroke: The Austrian Stroke Unit Registry. Neurology. 2010;74:136-141.
15. Teuschl Y, Brainin M, Matz K, Dachenhausen A, Ferrari J, Seyfang L, et al. Time trends in patient characteristics treated on acute stroke-units: results from the Austrian Stroke Unit Registry 2003-2011. Stroke. 2013;44:1070-1074.
16. Urra X, Arifio H, Llull L, Amaro S, Obach V, Cervera A, et al. The outcome of patients with mild stroke improves after treatment with systemic thrombolysis. PLoSOne. 2013;8.e59420.
17. Dhamoon MS, Moon YP, Paik MC, Boden- Albala B, Rundek T, Sacco RL, et al. Long- Term functional recovery after first ischemic stroke: The Northern Manhattan Study. Stroke. 2009;40:2805-2811.
18. Ingall TJ, O'Fallon WM, Asplund K, Goldfrank LR, Hertzberg VS, Louis TA, et al. Findings from the reanalysis of the NINDS tissue plasminogen activator for acute ischemic stroke treatment trial. Stroke. 2004;35:2418-2424.
19. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333:1581-1587.
20. Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke. 1993;24:35-41.
21. Bamford J, Sandercock P, Dennis M, Burn J, Warlow C. Classification and natural history of clinically identifiable subtypes of cerebral infarction. Lancet. 1991;337:1521-1526.
22. Kruetzelmann A, Siemonsen S, Gerloff C, Rosenkranz M, Rother J, Fiehler J, et al. Thrombolysis targeting MRJ defined tissue at risk in minor stroke. J Neurol Neunsurg Psychiatry. 2009;80:1156-1158.
23. Nesi M, Lucente G, Nencini F, Fancellu L, Inzitari D. Aphasia predicts unfavorable outcome in mild ischemic stroke patients and prompts thrombolytic treatment. J Stroke Cerebrovasc Dis. January 24, 2013. doi: 10.1016/j. jstrokecerebrovasdis.2012.11.018. Accessed September 30, 2013.
24. Strbian D, Ringleb P, Michel P, Breuer L, Ollikainen J, Murao K, et al. Ultra-early intravenous stroke thrombolysis: do all patients benefit similarly? Stroke. 2013;44:2913-2916.
25. Rajajee V, Kidwell C, Starkman S, Ovbiagele B, Alger JR, Villablanca P, et al. Early MRI and outcomes of untreated patients with mild or improving ischemic stroke. Neurology. 2006;67:980-984.
26. Gray CS, French JM, Bates D, Cartlidge NE, Venables GS, James OF. Recovery of visual fields in acute stroke: homonymous hemianopia associated with adverse prognosis. Age Ageing. 1989;18:419-421.
27. Zhang X, Kedar S, Lynn MJ, Newman NJ, Biousse V. Natural history of homonymous hemianopia. Neurology. 2006;66:901-905.
28. Paul NL, Simoni M, Chandratheva A, Rothwell PM. Population-based study of capsular warning syndrome and prognosis after early recurrent TIA. Neurology. 2012;79:1356-1362.
29. Fischer U, Arnold M, Nedeltchev K, Brekenfeld C, Ballinari P, Remonda L, et al. NIHSS score and arteriographic findings in acute ischemic stroke. Stroke. 2005;36:2121-2125.
30. Heldner MR, Zubler C, Mattle HP, Schroth G, Week A, Mono ML, et al. National Institutes of Health stroke scale score and vessel occlusion in 2152 patients with acute ischemic stroke. Stroke. 2013;44:1153-1157.
31. Khatri P, Khoury JC, Alwell K, Moomaw CH, Kissela BM, Woo D, et al. The public health impact of an effective acute treatment for mild ischemic strokes. Stroke. 2011;42:e66.